Every 8-K that Black Diamond Therapeutics, Inc. (BDTX) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 8-K covers material events a company has to report between its quarterly reports, so if you follow BDTX and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full BDTX filings page.
Black Diamond Therapeutics reported second-quarter 2026 results and highlighted new Phase 2 data for silevertinib in frontline non-classical EGFR-mutant NSCLC. At an April 11, 2026 cutoff, silevertinib showed an Objective Response Rate of 60%, CNS ORR of 86%, Disease Control Rate of 91%, preliminary median progression-free survival of 15.2 months, and no de novo brain metastases, with data supporting a 150 mg once-daily dose for pivotal development.
The company plans Phase 2 trial and FDA feedback updates in the fourth quarter of 2026 and is advancing a Phase 2 GBM combination study. Cash, cash equivalents, and investments were $110.5 million as of June 30, 2026, which is expected to fund operations into the second half of 2028. Second-quarter 2026 R&D expenses were $7.4 million (down from $9.3 million a year earlier), G&A expenses were $4.7 million (up from $4.1 million), net loss was $9.9 million (vs. $10.6 million), and net cash used in operations was $8.0 million (vs. $9.2 million).
Black Diamond Therapeutics, Inc. reported the results of its 2026 annual stockholder meeting. Of 57,301,774 common shares entitled to vote as of April 28, 2026, 44,690,495 were represented, establishing a quorum. Stockholders elected Shannon Campbell and Kapil Dhingra as Class III directors for three-year terms. They also ratified PricewaterhouseCoopers LLP as independent registered public accounting firm for the year ending December 31, 2026. Stockholders approved, on a non-binding basis, the compensation of the named executive officers and indicated a preference to hold this advisory vote every year. The company will conduct future say-on-pay votes annually until the next required vote on frequency.
Black Diamond Therapeutics filed an 8-K to share positive Phase 2 results for silevertinib as a frontline treatment for non-small cell lung cancer patients with EGFR non-classical mutations. The trial enrolled 43 treatment‑naïve patients at a 200 mg once‑daily oral dose, including 19 with brain metastases and seven with measurable CNS lesions.
As of an April 11, 2026 data cutoff, median follow‑up was 11.2 months and the study is ongoing. Management highlights robust preliminary progression‑free survival that they say far exceeds historical data for available therapies, and notes silevertinib prevented development of de novo brain metastases in this population. The data will be presented at the 2026 ASCO Annual Meeting and discussed on a company webcast for investors.
Black Diamond Therapeutics, Inc. reported first quarter 2026 results, showing a net loss of $9.0 million after earning $56.5 million in the same period of 2025, mainly because prior-year license revenue of $70.0 million did not recur. Cash, cash equivalents and investments were $118.3 million as of March 31, 2026, and the company believes this will fund operations into the second half of 2028. R&D and G&A expenses declined year over year as the company sharpened its focus on silevertinib. Clinically, Black Diamond dosed the first patient in its randomized Phase 2 trial of silevertinib in newly diagnosed EGFRvIII+ GBM and plans multiple silevertinib data presentations at the 2026 ASCO Annual Meeting.
Black Diamond Therapeutics reported a major financial turnaround for 2025, driven by $70.0 million in license revenue and sharply lower operating expenses. The company posted full-year net income of $22.4 million, compared to a net loss of $69.7 million in 2024, while ending 2025 with $128.7 million in cash, cash equivalents, and investments.
Research and development expenses fell to $33.6 million and general and administrative expenses to $16.6 million for the year, reflecting workforce and operational efficiencies. Management expects its cash balance to fund operations into the second half of 2028, supporting ongoing Phase 2 development of silevertinib in EGFR-mutant NSCLC and EGFR‑altered GBM, including a planned randomized GBM trial starting in the second quarter of 2026.
Black Diamond Therapeutics (BDTX) furnished an 8-K announcing financial results for the three and nine months ended September 30, 2025. The company issued a press release with the details, which is included as Exhibit 99.1. The information was furnished, not filed, under Item 2.02.